NASDAQ:MNTA - Momenta Pharmaceuticals Stock Price, Forecast & News

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its quarterly earnings data on Thursday, October, 31st. The biotechnology company reported ($0.59) EPS for the quarter, missing the consensus estimate of ($0.50) by $0.09. The biotechnology company had revenue of $6.40 million for the quarter, compared to analysts' expectations of $5.24 million. Momenta Pharmaceuticals had a negative return on equity of 59.82% and a negative net margin of 361.66%. The company's revenue for the quarter was down 57.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.65) earnings per share. View Momenta Pharmaceuticals' Earnings History.

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Friday, February 28th 2020. View Earnings Estimates for Momenta Pharmaceuticals.

8 brokerages have issued 12-month price targets for Momenta Pharmaceuticals' shares. Their forecasts range from $14.15 to $35.00. On average, they expect Momenta Pharmaceuticals' share price to reach $24.53 in the next year. This suggests a possible upside of 45.5% from the stock's current price. View Analyst Price Targets for Momenta Pharmaceuticals.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Momenta Pharmaceuticals in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Momenta Pharmaceuticals.

Headlines about MNTA stock have trended somewhat positive on Friday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Momenta Pharmaceuticals earned a daily sentiment score of 0.7 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Momenta Pharmaceuticals.

Some companies that are related to Momenta Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), Neurocrine Biosciences (NBIX), EXACT Sciences (EXAS), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL).

Based on aggregate information from My MarketBeat watchlists, some companies that other Momenta Pharmaceuticals investors own include Exelixis (EXEL), Amicus Therapeutics (FOLD), Synergy Pharmaceuticals (SGYP), ACADIA Pharmaceuticals (ACAD), Novavax (NVAX), Halozyme Therapeutics (HALO), ImmunoGen (IMGN), Portola Pharmaceuticals (PTLA), Gilead Sciences (GILD) and Omeros (OMER).

Momenta Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include State Street Corp (3.62%), Point72 Asset Management L.P. (2.61%), Great Point Partners LLC (1.01%), Peregrine Capital Management LLC (0.84%), Millennium Management LLC (0.43%) and Rhumbline Advisers (0.30%). Company insiders that own Momenta Pharmaceuticals stock include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, Ian Fier, Jo Ann Beltramello, Michelle Robertson, Santiago Arroyo, Scott M Storer and Young Kwon. View Institutional Ownership Trends for Momenta Pharmaceuticals.

MNTA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Squarepoint Ops LLC, Tocqueville Asset Management L.P., Barclays PLC and SG Americas Securities LLC. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Alejandra Carvajal, Anthony M Manning, Bruce Downey, Craig A Wheeler, Ian Fier, Jo Ann Beltramello, Michelle Robertson, Santiago Arroyo and Young Kwon. View Insider Buying and Selling for Momenta Pharmaceuticals.

MNTA stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Great Point Partners LLC, State of New Jersey Common Pension Fund D, Russell Investments Group Ltd., Millennium Management LLC, State of Alaska Department of Revenue, California Public Employees Retirement System and Peregrine Capital Management LLC. View Insider Buying and Selling for Momenta Pharmaceuticals.

Shares of MNTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of MNTA stock can currently be purchased for approximately $16.85.

Momenta Pharmaceuticals has a market capitalization of $1.67 billion and generates $75.59 million in revenue each year. The biotechnology company earns $-176,060,000.00 in net income (profit) each year or ($2.03) on an earnings per share basis. Momenta Pharmaceuticals employs 131 workers across the globe.View Additional Information About Momenta Pharmaceuticals.

The official website for Momenta Pharmaceuticals is http://www.momentapharma.com/.

Momenta Pharmaceuticals' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-491-9700 or via email at [email protected]